Abstract
Objetivo
Evaluar la eficiencia de paracetamol, indicado como tratamiento de primera línea para el dolor entre leve y moderado de la artrosis de cadera y rodilla, frente a rofecoxib, el inhibidor de la COX-2 más utilizado en España
Diseño
Modelo farmacoeconómico: análisis de minimización de costes basado en la información proporcionada por la revisión sistemática de la bibliografía
Emplazamiento
Nacional. España
Participantes
Pacientes con diagnóstico de artrosis de rodilla o cadera, con dolor entre leve y moderado, que demandan atención sanitaria en los servicios de atención primaria y que no presentan contraindicación para los tratamientos evaluados
Mediciones principales
Ante el supuesto de una eficacia equivalente entre paracetamol y rofecoxib, el modelo de minimización de costes se centró en el coste originado por la presencia de efectos adversos con cada fármaco tras aplicar un factor de corrección proporcional al número de sujetos incluidos en los estudios revisados y al número de efectos adversos observado
Resultados
El paracetamol minimiza los costes a los 3 meses y a 1 año respecto a rofecoxib. El coste anual promedio de paracetamol es de 307,95 euros (rango, 301,57–315,12) frente a los 574,59 euros (rango, 566,74–580,40) del tratamiento con rofecoxib. El principal inductor de costes tras el análisis de sensibilidad fue el coste de adquisición de los medicamentos, más que la tasa de incidencia de los efectos adversos
Conclusiones
El paracetamol es la primera opción de tratamiento frente a rofecoxib en el dolor artrósico entre leve y moderado desde el punto de vista del análisis económico basado en la minimización de costes, lo que confirma las recomendaciones que, con criterios de eficacia y seguridad, se indican en diversas guías de práctica clínica vigentes
Palabras clave: Artrosis, Paracetamol, Rofecoxib, Análisis de minimización de costes, Efectos adversos
Abstract
Objective
To assess the efficiency of paracetamol, indicated in first instance for light-to-moderate pain from hip and knee arthrosis, against rofecoxib, the COX-2 inhibitor most commonly used in Spain
Design
Pharmaco-economic model: costminimisation analysis based on the information provided by a systematic review of the literature
Setting
Spain: statewide
Participants
Patients with a diagnosis of knee or hip arthrosis, who demand health-care for light-to-moderate pain in the primary care services and present no counter-indication to the treatments under evaluation
Main measurements
Given the supposition of the equivalent efficacy of paracetamol and rofecoxib, the cost-minimisation model focused on the cost arising from the adverse side effects caused by the 2 drugs. A correction factor allowed for the number of subjects in the studies reviewed and the number of adverse side effects found
Results
Paracetamol was cheaper than rofecoxib at both 3 months and 1 year. The average cost of paracetamol per year was z.euro;307.95 (301.57–315.12) versus z.euro;574.59 (566.74–580.40) for rofecoxib treatment. The main cause of costs after the sensitivity analysis was the cost of acquiring the drugs, rather than the rate of incidence of adverse side effects
Conclusions
In terms of economic analysis based on cost minimisation, paracetamol was the first-preference treatment over rofecoxib for light-to-moderate arthrosis pain. This confirmed the recommendations which, under efficacy and safety criteria, are indicated in various clinical practice guidelines in force
Keywords: Arthrosis, Paracetamol, Rofecoxib, Cost-minimisation analysis, Adverse side effects
La financiación para la elaboración de este proyecto ha sido aportada por Bristol-Myers Squibb
Referencias bibliográficas
- 1.Hunsche E., Chancellor J.V., Bruce N. The burden of arthritis and nonsteroidal anti-inflammatory treatment. A European literature review. Pharmacoeconomics. 2001;19(Suppl 1):1–15. doi: 10.2165/00019053-200119001-00001. [DOI] [PubMed] [Google Scholar]
- 2.Elders M.J. The increasing impact of arthritis on public health. J Rheumatol Suppl. 2000;60:6–8. [PubMed] [Google Scholar]
- 3.Carmona L., Ballina J., Gabriel R., Laffon A. The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. Ann Rheum Dis. 2001;60:1040–1045. doi: 10.1136/ard.60.11.1040. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Badía X. Epidemiology and economic consequences of osteoarthritis. The European viewpoint. In: Reginster J.Y., Pelletiers J.P., Martel-Pelletiers J., Henrotin Y., editors. Osteoarthritis. Clinical and experimental aspects. Springer-Verlag; Berlin: 1999. [Google Scholar]
- 5.March L.M., Bachmeier C.J. Economics of osteoarthritis: a global perspective. Bailleres Clin Rheumatol. 1997;11:817–834. doi: 10.1016/s0950-3579(97)80011-8. [DOI] [PubMed] [Google Scholar]
- 6.Clarke A.E., Zowall H., Levinton C., Assimakopoulos H., Sibley J.T., Haga M. Direct and medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol. 1997;24:1051–1060. [PubMed] [Google Scholar]
- 7.Ganitas T.G., Sieber W.J., Weisman M. Self-reported cost of illness and health-related quality of life. Best pract. Benchmarking Health. 1997;2:57–62. [PubMed] [Google Scholar]
- 8.Nuitjen M.J.C., Starzewski J. Application of modelling studies. Pharmaeconomics. 1998;13:289–291. doi: 10.2165/00019053-199813030-00003. [DOI] [PubMed] [Google Scholar]
- 9.Pendlenton A., Arden N., Doherty M. EULAR recommendations for the management of knee osteoarthritis: report task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT) Ann Rheum Dis. 2000;59:936–944. doi: 10.1136/ard.59.12.936. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum. 2000;43:1905–1915. doi: 10.1002/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]
- 11.Eccles M. North of England evidence based guideline development project: summary guidelines for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. Bmj. 1998;317:526–530. doi: 10.1136/bmj.317.7157.526. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Colegio Oficial de Farmacéuticos . Catálogo de especialidades Farmacéuticas; Madrid: 2000. [Google Scholar]
- 13.Conselleria de Sanidad y Consumo . Orden de 7 de enero de. 1997. [Google Scholar]
- 14.Conselleria de Sanitat i Consum . 377 Orden de 18 de diciembre de. 1995. [Google Scholar]
- 15.García F., Dolsac J.L., Cebrián C., Lorente F., Bastasós J.C. Áreas Sanitarias 2 y 5; Zaragoza: 1994. Indicadores sanitarios económicos asistenciales en 2 áreas: el coste del producto de consulta en EAP. [Google Scholar]
- 16.Meneu R. Masson; Barcelona: 2002. Variabilidad de las decisiones médicas y su repercusión sobre las poblaciones. [Google Scholar]
- 17.Rivera M. Hospital 12 de Octubre; Madrid: 1992. Diseño de un sistema de cálculo y reparto de costes. [Google Scholar]
- 18.SOIKOS . 2001. Base de datos sobre costes sanitarios, versión. [Google Scholar]
- 19.Ehrich E.W., Schnitzer T.J., McIlwain H., Levy R., Wolfe F., Weisman M. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Journal Rheumatol. 1999;26:2438–2447. [PubMed] [Google Scholar]
- 20.Cannon G.W., Caldwell J.R., Holt P., McLean B., Seidenberg B., Bolognese J. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium. Arthritis Rheum. 2000;43:978–987. doi: 10.1002/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-0. [DOI] [PubMed] [Google Scholar]
- 21.Bradley J.D., Brandt K.D., Katz B.P., Kalasinski L.A., Ryan S.I. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med. 1991;325:87–91. doi: 10.1056/NEJM199107113250203. [DOI] [PubMed] [Google Scholar]
- 22.Amadio P., Cummings D.M. Evaluation of acetaminophen in the management of osteoarthritis of the knee. Curr Ther Res. 1988;34:59–66. [Google Scholar]
- 23.Kjaersgaard A., Nafei A., Skov O., Madsen F., Andersen H., Kroner K. Codeine plus paracetamol versus paracetamol in longer-term treatment of chronic pain due to osteoarthritis of the hip. A randomised, double-blind, multi-centre study. Pain. 1990;43:309–318. doi: 10.1016/0304-3959(90)90028-C. [DOI] [PubMed] [Google Scholar]
- 24.Saag K., Heijde D., Fisher C., Samara A., DeTora L., Bolognese J. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs. A 6-week and a 1-year trial in patients with osteoarthritis. Arch Family Med. 2000;9:1124–1134. doi: 10.1001/archfami.9.10.1124. [DOI] [PubMed] [Google Scholar]
- 25.Williams H.J., Ward J.R., Egger M.J., Neuner R., Brooks R.H., Clegg D.O. Comparison of naproxen and acetaminophen in a two-years study of treatment of osteoarthritis of the knee. Arthritis Rheum. 1993;36:1196–1206. doi: 10.1002/art.1780360904. [DOI] [PubMed] [Google Scholar]
- 26.National Institute for Clinical Excellence. Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis . Technology Applaisal Guidance; London: 2001. [Google Scholar]
- 27.Bardell E., Gordon M.M., Porter D. COX-2 inhibitors-implementation of the NICE guidelines. Rheumatology (Oxford) 2002;41:590–592. doi: 10.1093/rheumatology/41.5.590. [DOI] [PubMed] [Google Scholar]
- 28.Watson M., Brookes S., Kirwan J., Faulkner A. The Cochrane Library, Issue 2. Update Software; Oxford: 2001. Non-aspirin, nonsteroidal anti-inflammatory drugs for treating osteoarthritis of the knee. [Google Scholar]
- 29.Hawkey C., Lanas A. Doubt and certainty about nonsteroidal anti-inflammatory drugs in the year 2000: a multidisciplinary expert statement. Am J Med. 2001;110(Suppl 1):S79–S100. doi: 10.1016/s0002-9343(00)00651-3. [DOI] [PubMed] [Google Scholar]
- 30.Bjarnason I., Rainsford K.D. Are cyclooxygenase 2 inhibitors free of gastrointestinal side effects? Western J Med. 2001;175:267–268. doi: 10.1136/ewjm.175.4.267. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Bjarnason I., Rainsford K.D. COX-2 inhibitors and the gastrointestinal tract. Gut. 2001;48:451. doi: 10.1136/gut.48.4.451. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Geba G.P., Weavver A.L., Polis A.B., Dixon M.E., Schnitzer T.J. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. Jama. 2002;287:64–71. doi: 10.1001/jama.287.1.64. [DOI] [PubMed] [Google Scholar]
- 33.Towheed T.E., Judd M.J., Hochberg M.C., Wells G. Vol. 2. 2003. Acetaminophen for osteoarthritis. (Cochrane Database Syst Rev). CD004257. [DOI] [PubMed] [Google Scholar]